Northern Trust Corp I Mab Transaction History

Northern Trust Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$3.22 - $4.86 $2,389 - $3,606	-742 Reduced 5.39%	13,033 $54,000
Q3 2022 Nov 14, 2022	SELL	$4.01 - $12.34 $13,345 - $41,067	-3,328 Reduced 19.46%	13,775 $56,000
Q2 2022 Aug 12, 2022	SELL	$8.27 - $18.43 $581,910 - $1.3 Million	-70,364 Reduced 80.45%	17,103 $193,000
Q1 2022 May 13, 2022	BUY	$12.54 - $46.93 $39,037 - $146,093	3,113 Added 3.69%	87,467 $1.42 Million
Q4 2021 Feb 08, 2022	BUY	$45.28 - $74.5 $957,219 - $1.57 Million	21,140 Added 33.44%	84,354 $4 Million
Q3 2021 Nov 15, 2021	SELL	$57.18 - $84.43 $845,863 - $1.25 Million	-14,793 Reduced 18.96%	63,214 $4.58 Million
Q2 2021 Aug 13, 2021	BUY	$47.86 - $83.95 $3.73 Million - $6.55 Million	78,007 New	78,007 $6.55 Million

16.4M

1.9K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $108M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.